Cargando…

Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold

Effective therapies are urgently needed for COVID-19. Here we describe the identification of a new stable human immunoglobulin G1 heavy-chain variable (VH) domain scaffold that was used for the construction of a large library, lCAT6, of engineered human VHs. This library was panned against the recep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Zehua, Chen, Chuan, Li, Wei, Martinez, David R., Drelich, Aleksandra, Baek, Du-San, Liu, Xianglei, Mellors, John W., Tseng, Chien-Te, Baric, Ralph S., Dimitrov, Dimiter S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531518/ https://www.ncbi.nlm.nih.gov/pubmed/32544372 http://dx.doi.org/10.1080/19420862.2020.1778435

Ejemplares similares

Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice
por: Liu, Xianglei, et al.
Publicado: (2020)

Protocol for constructing large size human antibody heavy chain variable domain (V(H)) library and selection of SARS-CoV-2 neutralizing antibody domains
por: Chen, Chuan, et al.
Publicado: (2021)

Construction of a Large Size Human Immunoglobulin Heavy Chain Variable (VH) Domain Library, Isolation and Characterization of Novel Human Antibody VH Domains Targeting PD-L1 and CD22
por: Sun, Zehua, et al.
Publicado: (2022)

Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection
por: Li, Wei, et al.
Publicado: (2020)

High Potency of a Bivalent Human V(H) Domain in SARS-CoV-2 Animal Models
por: Li, Wei, et al.
Publicado: (2020)

Human Antibody Domains and Fragments Targeting Neutrophil Elastase as Candidate Therapeutics for Cancer and Inflammation-Related Diseases
por: Chu, Xiaojie, et al.
Publicado: (2021)

Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH Domains
por: Chen, Chuan, et al.
Publicado: (2022)

Potent and broad neutralization of SARS-CoV-2 variants of concern (VOCs) including omicron sub-lineages BA.1 and BA.2 by biparatopic human VH domains
por: Chen, Chuan, et al.
Publicado: (2022)

Effective killing of cells expressing CD276 (B7-H3) by a bispecific T cell engager based on a new fully human antibody
por: Liu, Xianglei, et al.
Publicado: (2021)

Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates
por: Kim, Ye-Jin, et al.
Publicado: (2023)

Bepridil is potent against SARS-CoV-2 In Vitro
por: Vatansever, Erol C., et al.
Publicado: (2020)

Neutral iodotriazoles as scaffolds for stable halogen-bonded assemblies in solution
por: Maugeri, Leonardo, et al.
Publicado: (2016)

Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody
por: Ying, Tianlei, et al.
Publicado: (2015)

An insulin growth factor-I/II-neutralizing monoclonal antibody in combination with epidermal growth factor receptor inhibitors potently inhibits tumor cell growth
por: Ma, Guofang, et al.
Publicado: (2022)

Neutralization mechanism of a highly potent antibody against Zika virus
por: Zhang, Shuijun, et al.
Publicado: (2016)

Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection In Vitro
por: Curreli, Francesca, et al.
Publicado: (2020)

Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies
por: Xiao, Xiaodong, et al.
Publicado: (2009)

Bepridil is potent against SARS-CoV-2 in vitro
por: Vatansever, Erol C., et al.
Publicado: (2021)

Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy
por: Lai, Yan-Da, et al.
Publicado: (2016)

Self-Masked Aldehyde Inhibitors of Human Cathepsin L Are Potent Anti-CoV-2 Agents
por: Zhu, Jiyun, et al.
Publicado: (2022)

The Antibody Germline/Maturation Hypothesis, Elicitation of Broadly Neutralizing Antibodies Against HIV-1 and Cord Blood IgM Repertoires
por: Prabakaran, Ponraj, et al.
Publicado: (2014)

Bispecific Engineered Antibody Domains (Nanoantibodies) That Interact Noncompetitively with an HIV-1 Neutralizing Epitope and FcRn
por: Gong, Rui, et al.
Publicado: (2012)

Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections
por: Ying, Tianlei, et al.
Publicado: (2015)

Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays
por: Curreli, Francesca, et al.
Publicado: (2021)

Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection
por: Agrawal, Anurodh Shankar, et al.
Publicado: (2016)

Human Antibody V(H) Domains Targeting GPNMB and VCAM-1 as Candidate Therapeutics for Cancers
por: Chu, Xiaojie, et al.
Publicado: (2023)

Human antibody V(H) domains targeting uPAR as candidate therapeutics for cancers
por: Chu, Xiaojie, et al.
Publicado: (2023)

Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies
por: Zhu, Xing, et al.
Publicado: (2021)

SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization
por: Mannar, Dhiraj, et al.
Publicado: (2022)

Crystal Structure of the Hendra Virus Attachment G Glycoprotein Bound to a Potent Cross-Reactive Neutralizing Human Monoclonal Antibody
por: Xu, Kai, et al.
Publicado: (2013)

Identification of Non-HIV Immunogens That Bind to Germline b12 Predecessors and Prime for Elicitation of Cross-clade Neutralizing HIV-1 Antibodies
por: Yang, Zheng, et al.
Publicado: (2015)

Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries
por: Pan, Yongbing, et al.
Publicado: (2021)

Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD
por: Ma, Hang, et al.
Publicado: (2022)

Human Domain Antibodies to Conserved Epitopes on HER2 Potently Inhibit Growth of HER2-Overexpressing Human Breast Cancer Cells In Vitro
por: Wang, Hongqian, et al.
Publicado: (2019)

A Subset Screen of the Compounds Australia Scaffold Library Identifies 7-Acylaminodibenzoxazepinones as Potent and Selective Hits for Anti-Giardia Drug Discovery
por: Hart, Christopher J. S., et al.
Publicado: (2022)

Preclinical assessment of a novel human antibody VH domain targeting mesothelin as an antibody-drug conjugate
por: Sun, Zehua, et al.
Publicado: (2023)

Strong Enrichment of Aromatic Residues in Binding Sites from a Charge-neutralized Hyperthermostable Sso7d Scaffold Library
por: Traxlmayr, Michael W., et al.
Publicado: (2016)

Epitope Mapping of M36, a Human Antibody Domain with Potent and Broad HIV-1 Inhibitory Activity
por: Wan, Chao, et al.
Publicado: (2013)

Co-Immunization with Multimeric Scaffolds and DNA Rapidly Induces Potent Autologous HIV-1 Neutralizing Antibodies and CD8(+) T Cells
por: Jaworski, Juan Pablo, et al.
Publicado: (2012)

Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses
por: Banach, Bailey B., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kjgef2i6aa9mfq87r02j430ujh